Form 4: PMV Pharmaceuticals Director Kirsten Flowers Reports Stock Option Grant
SEC Form 4 Filing
Director Kirsten Flowers of PMV Pharmaceuticals reports the acquisition of stock options.
Summary
- Kirsten Flowers, a director of PMV Pharmaceuticals, filed a Form 4 with the SEC.
- The filing reports the grant of stock options to Flowers on June 6, 2024.
- Flowers received options to purchase 67,500 shares of PMV Pharmaceuticals common stock at an exercise price of $1.65 per share.
- 22,500 shares vest on the earlier of June 6, 2025, or the day prior to the company's next annual meeting of stockholders.
- The remaining 45,000 shares vest in 36 equal monthly installments beginning on July 6, 2024.
- The options expire on June 5, 2034.
- Flowers also has a Power of Attorney appointing David H. Mack, Robert Ticktin, and Michael Carulli to act on her behalf for Section 16 reporting purposes.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, indicating confidence in the company's future performance. The sentiment is neutral to positive.
Positives
- The grant of stock options aligns the director's interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the director.
Industry Context
Stock option grants are a common form of compensation for directors and executives in publicly traded companies, aligning their interests with those of shareholders by incentivizing them to increase the company's stock value.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry.
- The vesting schedule and exercise price are typical for such grants, designed to incentivize long-term performance.
- Comparable companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals also utilize stock options as part of their executive compensation plans.
Stakeholder Impact
- The stock option grant could potentially increase shareholder value if the director's performance leads to an increase in the company's stock price.
- The grant incentivizes the director to work towards the company's success, which benefits employees and other stakeholders.
Key Dates
| Date | Description |
|---|---|
| 2024-01-05 | Date of Power of Attorney execution. |
| 2024-06-06 | Transaction date of stock option grant. |
| 2024-07-06 | Start date for monthly vesting of remaining 45,000 shares. |
| 2025-06-06 | Date when 22,500 shares vest (or the day prior to the next annual meeting). |
| 2034-06-05 | Expiration date of the stock options. |
| 2024-06-10 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.